Amgen (AMGN) Tops Q3 EPS by 57c, Reves Beat; Raises Outlook

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/5/2026

1. NVDA
2. PCVX
3. PTC
4. META
5. MSFT
6. SPY
7. GMAB
8. USO
9. GOOGL
10. AMD

Go back to Amgen (AMGN) Tops Q3 EPS by 57c, Reves Beat; Raises Outlook

Amgen Reports Third Quarter 2020 Financial Results

October 28, 2020 4:01 PM EDT

THOUSAND OAKS, Calif., Oct. 28, 2020 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced financial results for the third quarter of 2020.

Key results include:

Total revenues increased 12% to $6.4 billion in comparison to the third quarter of 2019 driven by higher volume growth, partially offset by lower net selling prices and the effects of the COVID-19 pandemic. Product sales increased 12% globally, driven by 18% volume growth across a number of our newer products, including Otezla® (apremilast), MVASI® (bevacizumab-awwb), KANJINTI® (trastuzumab-anns), and Repatha® (evolocumab), partially offset by declines in... More